Towards a Better-Tolerated Ketamine Treatment for Depression!

14.08.2023 Ketabon GmbH, a joint venture between HMNC Brain Health and Develco Pharma Schweiz AG, shares top-line results from the Phase 2 Trial KET01-02 (https://lnkd.in/eaG9SVJH) of prolonged-release oral ketamine treatment for Treatment-Resistant Depression (TRD), suitable for take-at-home treatment. The lead asset, KET01, induced a rapid and sustained improvement in depressive symptoms, combined with good tolerability, notably with minimal signs of dissociation. This innovation has the potential to transform the management of TRD, by providing an efficient and well-tolerated treatment alternative. We thank the clinical researchers across Germany, Poland, and the Czech Republic, as well as the patients participating in this study. For more details on the transformative potential of KET01, visit our website: https://lnkd.in/eX5psZpc

The release as fetched from its publisher. develco.ch ↗